Phenotypic antimicrobial resistance patterns in Pseudomonas aeruginosa and Acinetobacter: Results of a Multicenter Intensive Care Unit Surveillance Study, 1995-2000

Diagnostic Microbiology and Infectious Disease

Volumn 45, Issue 4, 2003, Pages 245-250

  Friedland, Ian ^a   Stinson, Lue ^a   Ikaiddi, Margaretmary ^a   Harm, Sandra ^a   Woods, Gail L ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Acinetobacter; Antimicrobial surveillance; Pseudomonas aeruginosa; Resistance

Indexed keywords

AMIKACIN; ANTIINFECTIVE AGENT; AZTREONAM; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; ERTAPENEM; GENTAMICIN; IMIPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TICARCILLIN; TIMENTIN; TOBRAMYCIN;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; CROSS RESISTANCE; HUMAN; INTENSIVE CARE; MULTICENTER STUDY; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ACINETOBACTER; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MICROBIAL; HUMANS; INTENSIVE CARE UNITS; MICROBIAL SENSITIVITY TESTS; MULTICENTER STUDIES; PHARMACOGENETICS; PROBABILITY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SENSITIVITY AND SPECIFICITY; UNITED STATES;

EID: 0038364026     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(02)00503-5     Document Type: Article

References (23)

1. Aires J.R., Kohler T., Nikaido H., Plesiat P. Involvement of an active efflux system in the natural resistance of Pseudomonas aeruginosa to aminoglycosides. Antimicrob Agents Chemother. 43:1999;2624-2628.
2. Ben-Mahrez K., Rejiba S., Belhadj C., Belhadj O. Beta-lactamase-mediated resistance to extended spectrum cephalosporins among clinical isolates of Pseudomonas aeruginosa. Res Microbiol. 150:1999;403-406.
3. Bergogne-Berezin E., Towner K.J. Acinetobacter species as nosocomial pathogens microbiological, clinical, and epidemiological features . Clin Microbiol Rev. 9:1996;148-165.
4. Fridkin S.K., Steward C.D., Edwards J.R., Pryor E.R., McGowna J.E. Jr, Archibald L.K., Gaynes R.P., Tenover F.C. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals Project ICARE Phase 2 . Clin Infect Dis. 29:1999;245-252.
5. Gales A.C., Jones R.N., Turnidge J., Rennie R., Ramphal R. Characterization of Pseudomonas aeruginosa isolates occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the Global SENTRY Antimicrobial Surveillance Program, 1997-1999 . Clin Infect Dis. 32:(Suppl 2):2001;S146-S155.
6. Gales A.C., Jones R.N., Forward K.R., Linares J., Sader H.S., Verhoef J. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999) . Clin Infect Dis. 32:(Suppl 2):2001;S104-113.
7. Jones R.N., Pfaller M.A. Ciprofloxacin as broad-spectrum empiric therapy-are fluoroquinolones still viable monotherapeutic agents compared with β-lactams Data from the MYSTIC Program (US) . Diagn Microbiol Infect Dis. 42:2002;213-215.
8. Livermore D.M., Woodford N. Carbapenemases a problem in waiting . Curr Opin Microbiol. 3:2000;489-498.
9. Livermore D.M. Acquired carbapenemases. J Antimicrob Chemother. 39:1997;673-676.
10. Livermore D.M. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa our worst nightmare . Clin Infect Dis. 34:2002;634-640.
11. Masuda N., Sakagawa E., Ohya S. Outer membrane proteins responsible for multiple drug resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 39:1995;645649.
12. Masuda N., Gotoh N., Ishii C., Sakagawa E., Ohya S., Nishino T. Interplay between chromosomal β-lactamase and the MexAB-OprM efflux system in intrinsic resistance to β-lactam agents in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 43:1999;400-402.
13. Mendes C., Turner P.J. Unit differences in pathogen occurrence arising from the MYSTIC Program European database (1997-2000). Diag Microbiol Infect Dis. 41:2001;191-196.
14. th ed. NCCLS document M7-A5. 2000;National Committee for Clinical Laboratory Standards, Wayne, PA.
15. Performance standard for antimicrobial susceptibility testing. Document M100-S12. 2002;National Committee for Clinical Laboratory Standards, Wayne, PA.
16. National Nosocomial Infections Surveillance (NNIS) system report data summary from October 1986-April 1998, issued June 1998 . Am J Infect Control. 26:1998;522-533.
17. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992-April 2000, issued June 2000. Am J Infect Control. 28:2000;429-448.
18. Nordmann P., Guibert M. Extended-spectrum β-lactamases in Pseudomonas aeruginosa. J Antimicrob Chemother. 42:1998;128-131.
19. Pfaller M.A., Jones R.N., Beidenbach D.J. Antimicrobial resistance trends in medical centers using carbapenems report of 1999 and 2000 results from the MYSTIC Program (USA) . Diag Microbiol Infect Dis. 41:2001;177-182.
20. Srikumar R., Kon T., Gotoh N., Poole K. Expression of Pseudomonas aeruginosa multidrug efflux pumps MexA-MexB-OprM and MexC-MexD-OprJ in a multidrug-sensitive Escherichia coli strain. Antimicrob Agents Chemother. 42:1998;65-71.
21. Takenouchi T., Sakagawa E., Sugawara M. Detection of gyrA mutations among 335 Pseudomonas aeruginosa strains isolated in Japan and their susceptibilities to fluoroquinolones. Antimicrob Agents Chemother. 43:1999;406-409.
22. Velasco M., Horcajada J.P., Mensa J., Moreno-Martinez A., Vila J., Martinez J.A., Ruiz J., Barranco M., Roig G., Soriano E. Decreased invasive capacity of quinolone-resistant Escherichia coli in patients with urinary tract infections. Clin Infect Dis. 33:2001;1682-1686.
23. Wisplinghoff H., Edmond M.B., Pfaller M.A., Jones R.N., Wenzel R.P., Seifert H. Nosocomial bloodstream infections caused by Acinetobacter species in United States hospitals clinical features, molecular epidemiology, and antimicrobial susceptibility . Clin Infect Dis. 31:2000;690-697.